Differentiation of PDLSCs and the development of periodontal disease are closely connected with the stimulation of inflammatory factors. The cardiovascular system, immune system, and skeletal system can all be affected by Rosuvastatin, which is a selective inhibitor of 3-hydroxy-3-methylglutarate monoacyl coenzyme reductase. The NF-κB signaling pathway can regulate stem cells' differentiation ability and inhibit the secretion of inflammatory factors by stem cells, as confirmed by existing studies. Our research found that in the inflammatory microenvironment of periodontitis, rosuvastatin sustained release by the RS-PC scaffold can effectively up-regulate the expression of miR-210, target and bind to p65, inhibit the inflammatory response regulated by the NF-κB signaling pathway, and promote osteogenic differentiation. The purpose of this project is to clarify the impact of miR-210 on the function of the PDLSCs in periodontitis conditions and its possible pathway in the PDLSCs. It became apparent that rosuvastatin targets the NF-κB signaling pathway, which controls miR-210, suppresses the release of inflammatory factors, and promotes osteogenic differentiation. The rosuvastatin in the RS-PC scaffold has been tested in animal experiments to investigate its sustained-release, anti-inflammatory, and alveolar bone repair abilities. The research findings offer a theoretical basis for investigating the mechanism behind periodontitis' occurrence and treatment methods.